読み込み中
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
前日終値
$229.23
+$6.54 · +2.94%
日中の時刻はETです。市場データは遅延する場合があります。
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
日中レンジ
現在 $229.23
52週レンジ
現在 $229.23
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
65
割安
センチメント
63
強気
リスク
29
中程度のリスク
モメンタム
61
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
日中レンジ
現在 $229.23
52週レンジ
現在 $229.23
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 6.92億 USD | 3.64億 USD | 2.67億 USD | 5117.4万 USD | 777.8万 USD |
| 売上原価 | 1.03億 USD | 4425.8万 USD | 4439.5万 USD | 1213.7万 USD | 352.3万 USD |
| 粗利益 | 5.89億 USD | 3.19億 USD | 2.22億 USD | 3903.7万 USD | 425.5万 USD |
| 研究開発 | 2.84億 USD | 3.07億 USD | 4.13億 USD | 3.8億 USD | 2.96億 USD |
| 販売・一般管理 | 4.36億 USD | 2.85億 USD | 2.59億 USD | 2.16億 USD | 1.6億 USD |
| 営業費用 | 7.19億 USD | 5.98億 USD | 6.78億 USD | 6.01億 USD | 4.56億 USD |
| 受取利息 | 1469.71万 USD | 1436.1万 USD | 1685.7万 USD | 742.6万 USD | 69.2万 USD |
| 支払利息 | 7746.41万 USD | 6550.4万 USD | 4406.5万 USD | 3068.2万 USD | 391.1万 USD |
| 減価償却費と償却費 | 1699.76万 USD | 1771.4万 USD | 1891.1万 USD | 1795.8万 USD | 1539.1万 USD |
| 営業利益 | −1.31億 USD | −2.79億 USD | −4.56億 USD | −5.62億 USD | −4.52億 USD |
| 純利益 | −2.19億 USD | −3.78億 USD | −4.81億 USD | −5.83億 USD | −3.84億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$317.42
上昇余地（38.47%）この株式へのエクスポージャーを報告している上場投資信託です。
T. Rowe Capital Appreciation Equity ETFTCAF1.7億1.88%91.1億 USD0.31%$43.59+0.90%
iShares Biotechnology ETFIBB1.06億1.01%108.2億 USD0.44%$206.49+3.00%
iShares Russell Mid-Cap Growth ETFIWP6300.3万0.32%200.95億 USD0.23%$143.1+1.56%
iShares Russell Mid-Cap ETFIWR4930.98万0.09%567.65億 USD0.18%$109.82+0.87%
iShares Russell 1000 Growth ETFIWF4200.89万0.03%1305.08億 USD0.18%$127.91+0.63%
Sapient Quality Select ETFSQS3244万2.28%14.24億 USD0.80%$28.5901-0.24%
Vanguard Russell 1000 Growth ETFVONG2013.05万0.04%543億 USD0.06%$131.69+0.63%
First Trust Health Care AlphaDEX FundFXH1497.28万1.34%11.13億 USD0.61%$130.15+1.37%T. Rowe Capital Appreciation Equity ETFTCAFiShares Biotechnology ETFIBBiShares Russell Mid-Cap Growth ETFIWPiShares Russell Mid-Cap ETFIWRiShares Russell 1000 Growth ETFIWFSapient Quality Select ETFSQSVanguard Russell 1000 Growth ETFVONGFirst Trust Health Care AlphaDEX FundFXHAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
